Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SSGJ-612 plus HER2-targeted ADC in HR-positive, HER2-low or ultra-low metastatic breast cancer
CTR20263054Phase 2Active
- Sponsor
- 3SBio
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-612 in breast cancer, sponsored by 3SBio. Started Aug 2026; status: active.
02
Drugs
SSGJ-612
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20263054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263054.